LANDRY ROBERT E 1585160 Data last updated 2024-05-11 06:58:14 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-25 | 2023-08-23 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 106.74 (REGN) | ||
| 2023-08-25 | 2023-08-23 | 2023-08-23 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 223.0 | 0.7 | 0.02 | 844.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 31699.0 | 106.74 (REGN) |
| 2023-12-12 | 2023-12-08 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-12 | 2023-12-08 | 2023-12-08 to 2023-12-11 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 4234.0 | 13.36 | 0.4 | 844.02 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 27465.0
|
107.13 (REGN) |
| 2023-12-14 | 2023-12-12 | 2023-12-13 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 1000.0 | 4.53 | 0.09 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 22084.0 | 107.13 (REGN) |
| 2023-12-14 | 2023-12-12 | 2023-12-12 to 2023-12-13 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 7104.0 | 24.96 | 0.66 | 858.18 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 21361.0
|
107.13 (REGN) |
| 2023-12-14 | 2023-12-12 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-29 | 2023-12-27 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-29 | 2023-12-27 | 2023-12-27 to 2023-12-28 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 1600.0 | 7.14 | 0.15 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 22419.0
|
107.13 (REGN) |
| 2023-12-29 | 2023-12-27 | 2023-12-27 to 2023-12-28 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1154.0 | 5.03 | 0.11 | 878.93 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 21807.0
|
107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 to 2024-01-03 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 1750.0 | 7.56 | 0.16 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23136.0
|
107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 to 2024-01-03 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1109.0 | 4.71 | 0.1 | 903.2 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 22448.0
|
107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-01-08 | 2024-01-04 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-01-08 | 2024-01-04 | 2024-01-04 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 342.0 | 1.49 | 0.03 | 917.05 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 22606.0 | 107.13 (REGN) |
| 2024-01-08 | 2024-01-04 | 2024-01-04 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 500.0 | 2.18 | 0.05 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 22948.0 | 107.13 (REGN) |
| 2024-01-17 | 2024-01-12 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 568.0 | 2.43 | 0.05 | 928.18 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 22838.0 | 107.13 (REGN) |
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 800.0 | 3.42 | 0.07 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23406.0 | 107.13 (REGN) |
| 2024-01-18 | 2024-01-17 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-01-18 | 2024-01-17 | 2024-01-17 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 500.0 | 2.14 | 0.05 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23338.0 | 107.13 (REGN) |
| 2024-01-18 | 2024-01-17 | 2024-01-17 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 354.0 | 1.52 | 0.03 | 932.34 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 22984.0 | 107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 to 2024-01-24 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1128.0 | 4.59 | 0.11 | 949.36 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 23456.0
|
107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 to 2024-01-24 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 1600.0 | 6.72 | 0.15 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23808.0
|
107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-02-02 | 2024-01-31 | 2024-01-31 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 282.0 | 1.18 | 0.03 | 953.42 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 23574.0 | 107.13 (REGN) |
| 2024-02-02 | 2024-01-31 | 2024-01-31 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 400.0 | 1.68 | 0.04 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23856.0 | 107.13 (REGN) |
| 2024-02-02 | 2024-01-31 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2024-02-06 | 2024-02-02 | 4 | Landry Robert E | EVP FINANCE CFO | holding | 270.0 | 0 | 0.03 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Landry Robert E | EVP FINANCE CFO | acq | 400.0 | 1.67 | 0.04 | 378.98 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 23974.0 | 107.94 (REGN) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-14 | 2023-12-12 | 2023-12-13 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1000.0 | 4.92 | 0.09 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 19337.0 | 107.13 (REGN) |
| 2023-12-29 | 2023-12-27 | 2023-12-27 to 2023-12-28 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1600.0 | 8.27 | 0.15 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 17737.0
|
107.13 (REGN) |
| 2024-01-04 | 2024-01-02 | 2024-01-02 to 2024-01-03 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1750.0 | 9.87 | 0.16 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 15987.0
|
107.13 (REGN) |
| 2024-01-08 | 2024-01-04 | 2024-01-04 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 500.0 | 3.13 | 0.05 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 15487.0 | 107.13 (REGN) |
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 800.0 | 5.17 | 0.07 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 14687.0 | 107.13 (REGN) |
| 2024-01-18 | 2024-01-17 | 2024-01-17 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 500.0 | 3.4 | 0.05 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 14187.0 | 107.13 (REGN) |
| 2024-01-25 | 2024-01-23 | 2024-01-23 to 2024-01-24 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 1600.0 | 11.28 | 0.15 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 12587.0
|
107.13 (REGN) |
| 2024-02-02 | 2024-01-31 | 2024-01-31 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 400.0 | 3.18 | 0.04 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 12187.0 | 107.13 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Landry Robert E | EVP FINANCE CFO | dsp | 400.0 | 3.28 | 0.04 | 378.98 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 11787.0 | 107.94 (REGN) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)